Afficher la notice abrégée

dc.creatorDardiotis E., Rikos D., Siokas V., Aloizou A.-M., Tsouris Z., Sakalakis E., Brotis A.G., Bogdanos D.P., Hadjigeorgiou G.M.en
dc.date.accessioned2023-01-31T07:50:56Z
dc.date.available2023-01-31T07:50:56Z
dc.date.issued2021
dc.identifier10.1080/00207454.2020.1750388
dc.identifier.issn00207454
dc.identifier.urihttp://hdl.handle.net/11615/73090
dc.description.abstractBackground: Α number of genetic variants are considered to confer susceptibility to Parkinson’s disease (PD). Rs75392628 (R47H), a rare variant of TREM2 gene, has been linked to PD, although its role on PD remains conflicting. Objective: Detection of a possible contribution of rs75392628 variant of TREM2 gene to PD risk. Methods: A total of 358 PD patients and 358 healthy controls genotyped for rs75392628. In addition, a meta-analysis was performed by merging our results with those from previous studies. Results: The rare variant of rs75932628 (47H) of TREM2 gene was not detected on cohort. Meta-analysis of a total of 9271 PD cases and 9777 controls across 14 independent PD data sets from 9 studies, including the present study, did not show any statistically significant effect of rs75392628 on PD risk (ORFE:1.54 95% CI:0.87-2.73. ORRE: 1.54, 95%CI: 0.71-3.32). Conclusions: Rs75392628 TREM2 variant is rather unlikely to be a major genetic risk contributor of PD. © 2020 Informa UK Limited, trading as Taylor & Francis Group.en
dc.language.isoenen
dc.sourceInternational Journal of Neuroscienceen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85083658946&doi=10.1080%2f00207454.2020.1750388&partnerID=40&md5=c1c34e75f7f30a7aa0756b3c84a6c308
dc.subjecttriggering receptor expressed on myeloid cells 2en
dc.subjectimmunoglobulin receptoren
dc.subjectmembrane proteinen
dc.subjectTREM2 protein, humanen
dc.subjectadulten
dc.subjectArticleen
dc.subjectcase control studyen
dc.subjectcohort analysisen
dc.subjectcontrolled studyen
dc.subjectfemaleen
dc.subjectgene locusen
dc.subjectgenetic associationen
dc.subjectgenetic risken
dc.subjectgenetic variabilityen
dc.subjectgenotypeen
dc.subjectGreek (citizen)en
dc.subjecthumanen
dc.subjectleukocyteen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmeta analysisen
dc.subjectParkinson diseaseen
dc.subjectageden
dc.subjectgenetic polymorphismen
dc.subjectgeneticsen
dc.subjectGreeceen
dc.subjectmiddle ageden
dc.subjectParkinson diseaseen
dc.subjectAgeden
dc.subjectCase-Control Studiesen
dc.subjectFemaleen
dc.subjectGreeceen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMembrane Glycoproteinsen
dc.subjectMiddle Ageden
dc.subjectParkinson Diseaseen
dc.subjectPolymorphism, Geneticen
dc.subjectReceptors, Immunologicen
dc.subjectTaylor and Francis Ltd.en
dc.titleAssessment of TREM2 rs75932628 variant’s association with Parkinson’s disease in a Greek population and Meta-analysis of current dataen
dc.typejournalArticleen


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée